ClinicalTrials.gg
CompletedNCT07300280Updated Nov 6, 2026

A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)

A Phase 1 interventional study of MK-0616A and Enlicitide in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

Updated Nov 6, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This goal of this trial is to learn about two medicines, enlicitide and rosuvastatin, in healthy people. Researchers will compare the amounts of enlicitide and rosuvastatin in a person's body over time, when they are given as separate medicines and when they are combined into one tablet.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

The main inclusion criteria include but are not limited to the following:

  • Is medically healthy with no medical history
  • Is a non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to study entry

Exclusion Criteria:

  • Is unable to refrain from or anticipates the use of any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to study entry
  • Is a female participant of
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Enlicitide + Rosuvastatin Part 1

    Participants in Part 1 will receive a single dose of enlicitide tablet coadministered with a single dose of rosuvastatin tablet

    Drug: Enlicitide · Drug: Rosuvastatin

  • Experimental
    MK-0616A Part 1

    Participants in Part 1 will receive a single dose of MK-0616A

    Drug: MK-0616A

  • Experimental
    Enlicitide + Rosuvastatin Part 2

    Participants in Part 2 will receive a single dose of enlicitide tablet coadministered with a single dose of rosuvastatin tablet

    Drug: Enlicitide · Drug: Rosuvastatin

  • Experimental
    MK-0616A Part 2

    Participants in Part 2 will receive a single dose of MK-0616A formulation B

    Drug: MK-0616A

Interventions

  • DrugMK-0616A

    Enlicitide/rosuvastatin fixed dose combination (FDC) or enlicitide/rosuvastatin FDC formulation B oral tablets

    Also known as: enlicitide/rosuvastatin calcium

  • Oral tablet

    Also known as: MK-0616

  • Oral tablet

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Enlicitide

    Blood samples will be collected to determine the AUC0-inf of enlicitide in plasma

    Time frame: Pre dose and at designated time points up to 168 hours post dose

  2. AUC0-Inf of Rosuvastatin

    Blood samples will be collected to determine the AUC0-inf of rosuvastatin in plasma

    Time frame: Pre dose and at designated time points up to 168 hours post dose

  3. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Enlicitde

    Blood samples will be collected to determine the AUC0-last of enlicitide in plasma

    Time frame: Pre dose and at designated time points up to 168 hours post dose

  4. AUC0-Last of Rosuvastatin

    Blood samples will be collected to determine the AUC0-last of rosuvastatin in plasma

    Time frame: Pre dose and at designated time points up to 168 hours post dose

  5. Maximum Plasma Concentration (Cmax) of Enlicitide

    Blood samples will be collected to determine the cmax of enlicitide in plasma

    Time frame: Pre dose and at designated time points up to 168 hours post dose

  6. Cmax of Rosuvastatin

    Blood samples will be collected to determine the cmax of rosuvastatin in plasma

    Time frame: Pre dose and at designated time points up to 168 hours post dose

Secondary outcomes

  1. Number of Participants who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 9 weeks

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 8 days after first dose

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Oct 2026, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Dec 23, 2025
StartActual
Dec 29, 2025
Primary completionActual
Oct 14, 2026
CompletionActual
Oct 21, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07300280
Responsible party
Sponsor
First posted
Dec 23, 2025
Start date
Dec 29, 2025
Primary completion
Oct 14, 2026
Completion
Oct 21, 2026
Last update
Nov 6, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Enlicitide · Rosuvastatin

Start the discussion